Eli Lilly and Company

Semagacestat (LY450139) was a candidate drug for a causal therapy against Alzheimer's disease.

Gemcitabine (pronunciation: jem-SITE-a-been) is a nucleoside analog used in chemotherapy.

Thiomersal (INN), commonly known in the U.

LY-293284 is a research chemical developed by the pharmaceutical company Eli Lilly and used for scientific studies.

NPH insulin, also known as isophane insulin (INN) and by , is an intermediate-acting insulin given to help control the blood sugar level of people with diabetes.

Erythromycin is an antibiotic useful for the treatment of a number of bacterial infections.

Lysergic acid diethylamide (LSD), also known as acid, is a psychedelic drug known for its psychological effects.

Methadone, sold under the brand names Dolophine among others, is an opioid used to treat pain and as maintenance therapy or to help with detoxification in people with opioid dependence.

Olanzapine (originally branded Zyprexa) is an atypical antipsychotic.

Penicillin (PCN or pen) is a group of antibiotics which include penicillin G (intravenous use), penicillin V (oral use), procaine penicillin, and benzathine penicillin (intramuscular use).

Vancomycin is an antibiotic used to treat a number of bacterial infections.

Lipoic acid (LA), also known as α-lipoic acid and alpha lipoic acid (ALA) and thioctic acid is an organosulfur compound derived from octanoic acid.

Pioglitazone (brand name Actos) is a prescription drug of the thiazolidinedione (TZD) class with hypoglycemic (antihyperglycemic, antidiabetic) action to treat diabetes.

Dextropropoxyphene is an analgesic in the opioid category, patented in 1955 and manufactured by Eli Lilly and Company.

Duloxetine, sold under the brand name Cymbalta among others, is a serotonin-norepinephrine reuptake inhibitor (SNRI) created by Eli Lilly.

Ergocalciferol (vitamin D2) is a form of vitamin D.

Oritavancin (INN, also known as LY333328, Orbactiv) is a novel semisynthetic glycopeptide antibiotic for the treatment of serious Gram-positive bacterial infections.

Exenatide (/ɛɡzˈɛnətaɪd/, INN, marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2.

Cefalexin, also spelled cephalexin, is an antibiotic that can treat a number of bacterial infections.

Fluoxetine, also known by trade names Prozac and Sarafem among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.

Ractopamine is a feed additive to promote leanness in animals raised for their meat.

Atomoxetine (brand name: Strattera) is a drug which is approved for the treatment of attention deficit hyperactivity disorder (ADHD).

Vincristine, also known as leurocristine and marketed under the brandname Oncovin among others, is a chemotherapy medication used to treat a number of types of cancer.

Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.

Tadalafil is a PDE5 inhibitor marketed in pill form for treating erectile dysfunction (ED) under the name Cialis, and under the name Adcirca for the treatment of pulmonary arterial hypertension.

Benoxaprofen, also known as Benoxaphen, is a chemical compound with the formula C16H12ClNO3.

Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties.

Pruvanserin (EMD-281,014, LY-2,422,347) is a selective 5-HT2A receptor antagonist which was under development by Eli Lilly and Company for the treatment of insomnia.

Izonsteride (LY-320,236) is a selective inhibitor of the 5α-reductase, with dual effects on both the type I and type II isoforms of the enzyme.

LY-2183240 is a drug which acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide.

PPPA, or 3-phenoxy-3-phenylpropan-1-amine, is a drug which is described as an antidepressant.

Dapoxetine, marketed as Priligy and Westoxetin, among and other brands, is the first compound developed specially for the treatment of premature ejaculation (PE) in men 18–64 years old.

Diethylstilbestrol (DES) (INN, USAN, BAN), also known formerly (and inappropriately) as stilboestrol (BAN), is a synthetic, non-steroidal estrogen of the stilbestrol group that was first synthesized in 1938.

Regular insulin includes regular human insulin also known as human insulin (regular) and is a short acting insulin.

Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company.

LY-307,452 is a drug used in neuroscience research, which was among the first compounds found that acts as a selective antagonist for the group II metabotropic glutamate receptors (mGluR2/3), and was useful in early studies of this receptor family, although it has largely been replaced by newer drugs such as LY-341,495.

Insulin lispro (marketed by Eli Lilly and Company as Humalog) is a fast acting insulin analog.

Xipamide is a sulfonamide diuretic drug marketed by Eli Lilly under the trade names Aquaphor (in Germany) and Aquaphoril (in Austria).

Raloxifene (marketed as Evista by Eli Lilly and Company) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast.

Eglumegad (LY354740) is a research drug developed by Eli Lilly and Company, which is being investigated for its potential in the treatment of anxiety and drug addiction.

Blosozumab binds SOST, a negative regulator of osteoblast activity.

Dirucotide (also known as MBP8298) was developed by two research scientists (Dr. Kenneth G. Warren, MD, FRCP(C) & Ingrid Catz, Senior Scientist) at the University of Alberta for the treatment of Multiple Sclerosis (MS).

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy being investigated by Eli Lilly and Company.

Lysergic acid 2-butyl amide (2-Butyllysergamide, LSB) is an analogue of LSD originally developed by Richard Pioch at Eli Lilly in the 1950s, but mostly publicised through research conducted by the team led by David E.

LY-272,015 is a beta-carboline derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor.

LY-344,545 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR5.

Cetuximab (INN) is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer.

Teriparatide is a recombinant form of parathyroid hormone consisting of the first (N-terminus) 34 amino acids, which is the bioactive portion of the hormone.

Secobarbital sodium (marketed by Eli Lilly and Company, and subsequently by other companies as described below, under the brand name Seconal) is a barbiturate derivative drug that was patented in 1934 in the US.

Edivoxetine (INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment.

LY-404,187 (or LY404187) is an ampakine (or "AMPA receptor potentiator") developed by Eli Lilly and Company.

Lasmiditan (codenamed COL-144) is an investigational drug for the treatment of acute migraine.

Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a single capsule containing the atypical antipsychotic olanzapine and the selective serotonin reuptake inhibitor (SSRI) fluoxetine.

Tezampanel (INN, USAN) (code names LY-293,558, NGX-424) is a drug originally developed by Eli Lilly which acts as a competitive antagonist of the AMPA and kainate subtypes of the ionotropic glutamate receptor family, with selectivity for the GluR5 subtype of the kainate receptor.

LY-487,379 is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR2.

Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.

Prasugrel (trade name Effient in the US and India, and Efient in the EU) is a pharmaceutical drug that acts as a platelet inhibitor and is used to prevent thrombosis (blood clotting).

LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1.

Cefalotin (INN) /ˌsɛfəˈloʊtᵻn/ or cephalothin (USAN) /ˌsɛfəˈloʊθᵻn/ is a first-generation cephalosporin antibiotic.

Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

Methylhexanamine (trade names Forthane, Geranamine) or methylhexamine, commonly known as 1,3-dimethylamylamine (1,3-DMAA) or simply dimethylamylamine (DMAA), is an indirect sympathomimetic drug invented and developed by Eli Lilly and Company and marketed as an inhaled nasal decongestant from 1944 until it was voluntarily withdrawn from the market in 1983.

Idiopathic short stature (ISS) refers to extreme short stature that does not have a diagnostic explanation (idiopathic designates a condition that is unexplained or not understood) after an ordinary growth evaluation.

Ixekizumab (trade name Taltz) is an injectable drug for the treatment of autoimmune diseases.

Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI).

LY-334370 is a selective 5-HT1F receptor agonist which was under development by Eli Lilly and Company for the treatment of migraine headaches.

LY-503,430 is an ampakine drug developed by Eli Lilly.

Kappadione is a Vitamin K derivative.

LY-341,495 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as a potent and selective orthosteric antagonist for the group II metabotropic glutamate receptors (mGluR2/3).

LY-379,268 is a drug that is used in neuroscience research, which acts as a potent and selective agonist for the group II metabotropic glutamate receptors (mGluR2/3).

CECXG (3'-ethyl-LY-341,495) is a research drug which acts as a potent and selective antagonist for the group II metabotropic glutamate receptors (mGluR2/3), with reasonable selectivity for mGluR3.

LY-367,265 is a drug developed by Eli Lilly, which acts as both a potent and selective antagonist at the serotonin 5-HT2A receptor, and also a selective serotonin reuptake inhibitor (SSRI).

LY-215,840 is an ergoline derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT2 and 5-HT7 receptors.

N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed.

Empagliflozin/linagliptin is a drug combination used for the treatment of type II diabetes.